bevacizumab + cisplatin + etoposide (Genentech)

bevacizumab + cisplatin + etoposide is a combination chemotherapy regimen investigated by Genentech for the treatment of extensive-stage small cell lung cancer (SCLC). The regimen consists of bevacizumab (Avastin), a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis, combined with standard cytotoxic chemotherapy (cisplatin or carboplatin and etoposide). In the Phase II SALUTE trial, the addition of bevacizumab to platinum-etoposide chemotherapy demonstrated an improvement in progression-free survival but failed to show a significant benefit in overall survival for patients with previously untreated extensive-stage SCLC. The treatment typically involves four cycles of the combination followed by bevacizumab maintenance therapy until disease progression or unacceptable toxicity.

Other names

bevacizumab + carboplatin + etoposideSALUTE regimen